The world's first basal insulin GLP-1RA injection Novozymes(R) launched in China

BEIJING, March 5, 2022 /PRNewswire/ -- The total number of adults with diabetes in China ranks first in the world, reaching 140 million[1].

The world's first basal insulin GLP-1RA injection Novozyme® officially launched in China

Blood sugar fluctuations are harmful, and "high-quality compliance" is the key to sugar control

100 years ago, the discovery of insulin turned diabetes from an incurable disease into a manageable disease

For diabetic patients, frequent and excessive blood sugar fluctuations are even more serious than persistent hyperglycemia, which will continue to damage vascular endothelial cells throughout the body and increase the risk of diabetic complications, which may cause blindness, kidney failure, heart attack, Serious consequences such as stroke and lower limb amputation not only affect the quality of life of patients, but also increase the economic burden on families and society [4]

Therefore, high blood sugar control is the first priority of blood sugar management in diabetic patients.

The rate of glycated hemoglobin reaching the standard is nearly 90%, and it has been unanimously affirmed by domestic and foreign guidelines.

The world's first basal insulin GLP-1RA injection, Novozyme®, recently launched.

In order to further verify the efficacy and safety of Novozyme® in the Chinese population, the DUALⅠ&Ⅱ China study was also carried out in China, and the results confirmed that this drug can significantly improve blood sugar control in Chinese patients with type 2 diabetes, and has both low risk of hypoglycemia and low risk of hypoglycemia.

Novozymes® has achieved access to medicines in many provinces and cities across the country

Novozymes® has achieved access to medicines in many provinces and cities across the country

Zhou Xiaping, global senior vice president of Novo Nordisk and president of Greater China, said: "Novo Nordisk has been committed to its century-old aspiration and never stops innovating

Novozymes®

Novoyi® is the world's first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection, consisting of insulin degludec and liraglutide[7]

[1] Yongze L, et al.

[2] Wang L, et al.

[3] Instructions for insulin degludec and liraglutide injection

[4] IDF Diabetes Atlas 2021.

[5] Diabetes Branch of Chinese Medical Association.

[6] Pei Y, et al.

[7] Gough S, et al.

[8] Østergaard L, et al.

[9] Miller E, et al.
Diabetes Obes Metab.
2019 Dec;21(12):2643-2650.

Source: Novo Nordisk

The original is abridged